167 related articles for article (PubMed ID: 14529472)
1. Altered protein acetylation in polyglutamine diseases.
Bodai L; Pallos J; Thompson LM; Marsh JL
Curr Med Chem; 2003 Dec; 10(23):2577-87. PubMed ID: 14529472
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
[TBL] [Abstract][Full Text] [Related]
3. Polyglutamine disease: acetyltransferases awry.
Hughes RE
Curr Biol; 2002 Feb; 12(4):R141-3. PubMed ID: 11864588
[TBL] [Abstract][Full Text] [Related]
4. Altered acetylation in polyglutamine disease: an opportunity for therapeutic intervention?
Taylor JP; Fischbeck KH
Trends Mol Med; 2002 May; 8(5):195-7. PubMed ID: 12067622
[TBL] [Abstract][Full Text] [Related]
5. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs.
Hassig CA; Schreiber SL
Curr Opin Chem Biol; 1997 Oct; 1(3):300-8. PubMed ID: 9667866
[TBL] [Abstract][Full Text] [Related]
6. [Assay for inhibitory activity of histone deacetylase].
Yoshida M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
[TBL] [Abstract][Full Text] [Related]
7. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.
Langley B; Gensert JM; Beal MF; Ratan RR
Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):41-50. PubMed ID: 15723612
[TBL] [Abstract][Full Text] [Related]
8. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation.
Chou AH; Chen YL; Hu SH; Chang YM; Wang HL
Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423
[TBL] [Abstract][Full Text] [Related]
9. [Molecular biology of polyglutamine diseases].
Owecki M; Kozubski W
Postepy Hig Med Dosw; 2002; 56(6):779-88. PubMed ID: 12661407
[TBL] [Abstract][Full Text] [Related]
10. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
11. Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein.
Taylor JP; Taye AA; Campbell C; Kazemi-Esfarjani P; Fischbeck KH; Min KT
Genes Dev; 2003 Jun; 17(12):1463-8. PubMed ID: 12815067
[TBL] [Abstract][Full Text] [Related]
12. Histone acetylation and recruitment of serum responsive factor and CREB-binding protein onto SM22 promoter during SM22 gene expression.
Qiu P; Li L
Circ Res; 2002 May; 90(8):858-65. PubMed ID: 11988486
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors reduce polyglutamine toxicity.
McCampbell A; Taye AA; Whitty L; Penney E; Steffan JS; Fischbeck KH
Proc Natl Acad Sci U S A; 2001 Dec; 98(26):15179-84. PubMed ID: 11742087
[TBL] [Abstract][Full Text] [Related]
14. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.
Anne-Laurence B; Caroline R; Irina P; Jean-Philippe L
Subcell Biochem; 2007; 41():263-93. PubMed ID: 17484132
[TBL] [Abstract][Full Text] [Related]
15. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis.
Saha RN; Pahan K
Cell Death Differ; 2006 Apr; 13(4):539-50. PubMed ID: 16167067
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors and cancer: from cell biology to the clinic.
Hess-Stumpp H
Eur J Cell Biol; 2005 Mar; 84(2-3):109-21. PubMed ID: 15819394
[TBL] [Abstract][Full Text] [Related]
17. [Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders].
Jiang H; Jia D; Tang B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):52-5. PubMed ID: 20140868
[TBL] [Abstract][Full Text] [Related]
18. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
Ganai SA; Banday S; Farooq Z; Altaf M
Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
[TBL] [Abstract][Full Text] [Related]
19. Roles of histone acetyltransferases and deacetylases in gene regulation.
Kuo MH; Allis CD
Bioessays; 1998 Aug; 20(8):615-26. PubMed ID: 9780836
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
